March 21, 2023 4:51pm
Cell and gene therapy equities gain yet, still shuffle with some fluctuating to the downside
News: Intellia Therapeutics (NTLA +$1.52) the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE) - a rare, genetic disorder characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. NTLA-2002 is an in vivo CRISPR-based investigational therapy designed to inactivate the target gene, kallikrein B1 (KLKB1), to potentially prevent life-threatening swelling attacks in people with HAE.
Pre-open indication Results: 3 Hits and 1 Miss
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +316.02 points (+0.98%), the S&P closed UP +51.30 points (+1.30%) while the Nasdaq closed UP +184.57 points (+1.58%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes rose Tuesday, building on Monday’s rally following U.S. and European efforts to stabilize the banking system.
Prior to the Silicon Valley Bank (SVB) debacle and potential fraud, policymakers are poised to hike rates by 25 basis points given the crisis in the banking sector.
Economic Data docket: Sales of previously owned homes rose 14.5% in February compared with January, according to a seasonally adjusted count by the National Association of Realtors. The average rate on the popular 30-year fixed loan hovered in the low 6% range throughout January after reaching a high of 7% last fall.
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences
- Tuesday’s advance/decline line opened positive at 23 up/ 10 down and 2 flats, stayed positive with 21 up/ 13 down and 1 flat at the mid-day, ending with a positive close of 21/13 and 1 flat
- Monday’s advance/decline line opened negative at 11 up/ 22 down and 2 flats, stayed negative with 10 up/ 22 down and 3 flats at the mid-day, ending with a negative close of 13/21 and 1 flat
Pre-open indication Results: 3 Hits <Compass Therapeutics (CMPX -$0.03), Sage Therapeutics (SAGE -$0.69), Verve Therapeutics (VERV +$0.34)> 1 Miss <AxoGen (AXGN +$0.43)>
52-week low:
· Caribou Biosciences (CRBU) at $4.81
· Solid Biosciences (SLDB) at $3.60
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … https://www.regmedinvestors.com/articles/12843 - 26 of 35
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB was up +0.12% and the XBI was down -1.03%
- Monday, the IBB was up +1.08% and the XBI was up +0.37%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was down -2.59 points or -10.72% at 21.56
- Monday was down -1.38 points or -5.41% at 24.13
Closing Down (13 of 13):
- Editas Medicine (EDIT -$0.14 after Monday’s -$0.17),
- Ultragenyx (RARE -$0.66 after Monday’s +$0.47),
- Sage Therapeutics (SAGE -$0.69 after Monday’s +$1.23),
- Fate Therapeutics (FATE-$0.14),
- Mesoblast (MESO -$0.08 after Monday’s +$0.06),
- Chinook Therapeutics (KDNY -$0.08 after Monday’s -$0.17),
- Caribou Biosciences (CRBU -$0.07),
- Solid Biosciences (SLDB -$0.04 after Monday’s -$0.43),
- Sangamo Therapeutics (SGMO -$0.03),
- Agenus (AGEN -$0.01),
- Adverum Biotechnologies (ADVM -$0.0041),
- Verastem (VSTM -$0.0025),
- Bellicum Pharmaceuticals (BLCM -$0.0001)
Flat (1)
- Biostage (OTCQB: BSTG)
Closing Up (10 of 21):
- Alnylam Pharmaceuticals (ALNY +$2.91 after Monday’s +$2.07),
- Intellia Therapeutics (NTLA +$1.52 after Monday’s -$1.57),
- BioLife Solutions (BLFS +$1.29 after Monday’s -$0.54),
- CRISPR Therapeutics (CRSP +$0.60 after Monday’s -$1.28)
- Vericel (VCEL +$0.46 after Monday’s +$0.63),
- AxoGen (AXGN +$0.43 after Monday’s +$0.26),
- Prime Medicine (PRME +$0.38 after Monday’s +$0.61),
- Verve Therapeutics (VERV +$0.34),
- Beam Therapeutics (BEAM +$0.17 after Monday’s -$0.99),
- Homology Medicine (FIXX +$0.15),
Q1/23 – March
- Tuesday closed positive with 21 incliner, 13 decliners and 1 flat
- Monday closed negative with 13 incliner, 21 decliners and 1 flat
The BOTTOM LINE: I try to keep it simple … and short!
After Monday’s sector decline, Tuesday’s sector response was advancing share pricing.
A quote from the master, “Jeremy Grantham expects stocks to plunge and a recession to hit as the "everything bubble" bursts. The investor warns the S&P 500 could halve in value to around 2,000 points in a worst-case scenario. Grantham advised against betting on US stocks for the short term, and touted emerging markets. Jeremy Grantham has warned the implosion of an "everything bubble" could tank the S&P 500 by up to 50%, and plunge the US economy into a painful recession.” <Business Insider>
The rush of Q4 and FY22 earnings to release is on … 26 of my 35 covered have reported.
Upcoming Q4 earnings reporting will present challenges to share pricing.
· Nine (9) more releases forthcoming of my 35 covered companies
· Brainstorm Cell Therapeutics (BCLI) 3/30 - Thursday
WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.
Remember, there are four (4) phases of the stock cycle: accumulation; markup; distribution; and markdown.
As I have stated, “What goes up with ceremony, goes down with disdain followed by the opposite effect.”
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone!
Biostage (OTCQB: BSTG) – still pumping the volume and TRYING to promote the share price!!
Tuesday closed flat with 2,085 shares traded after Monday closed down -$0.10 with 498 shares traded, Friday closed up +$0.45 with 1,590 shares traded following Thursday’s +$0.09 with 3,924 shares traded after Wednesday closed down -$0.44 with 4,166 shares traded and last Tuesday closed down -$0.02 with 5,105 shares traded <3-month average volume = 1,710 shares>
· Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold??
· Let’s also welcome a NEW accounting firm – the fourth (4th) in five (5) years. When will they resign …??
· Where is the SEC??
· NEW Auditors must consider whether there is substantial doubt about a company’s ability to continue as a going concern, an assessment of the company’s viability over the next year.
· Continuing as an “going concern”!
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
